Phosphodiesterase 4 Inhibitors
"Phosphodiesterase 4 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
| Descriptor ID |
D058988
|
| MeSH Number(s) |
D27.505.519.389.735.374
|
| Concept/Terms |
Phosphodiesterase 4 Inhibitors- Phosphodiesterase 4 Inhibitors
- Inhibitors, Phosphodiesterase 4
- PDE4 Inhibitors
- Inhibitors, PDE4
- Phosphodiesterase Type 4 Inhibitors
- PDE-4 Inhibitors
- Inhibitors, PDE-4
- PDE 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 4 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 4 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 4 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 4 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 4 Inhibitors" by people in Profiles.
-
Norris MR, Bielory L. Chronic tearing induced by apremilast. Ann Allergy Asthma Immunol. 2018 09; 121(3):375.
-
Forkuo GS, Kim H, Thanawala VJ, Al-Sawalha N, Valdez D, Joshi R, Parra S, Pera T, Gonnella PA, Knoll BJ, Walker JK, Penn RB, Bond RA. Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by ?2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. Am J Respir Cell Mol Biol. 2016 08; 55(2):234-42.
-
White WB, Cooke GE, Kowey PR, Calverley PMA, Bredenbr?ker D, Goehring UM, Zhu H, Lakkis H, Mosberg H, Rowe P, Rabe KF. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013 Sep; 144(3):758-765.
-
Moodley T, Wilson SM, Joshi T, Rider CF, Sharma P, Yan D, Newton R, Giembycz MA. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Mol Pharmacol. 2013 Apr; 83(4):894-906.
-
Wouters EF, Bredenbr?ker D, Teichmann P, Brose M, Rabe KF, Fabbri LM, G?ke B. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 Sep; 97(9):E1720-5.